- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04668625
Risk of Infection of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), COVID-19, in a Massive Musical Show With Transmission Prevention Measures
Risk of Infection of SARS-CoV-2 in a Massive Musical Show With Transmission Prevention Measures: Randomized Study
The coronavirus disease 2019 (COVID-19) outbreak, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan in December 2019 and has spread globally, representing a serious threat to public health. While waiting for highly effective treatments or the development of an effective vaccine, it is necessary to reactivate key economic activities that are related to leisure and culture in an environment that is safest for the participants.
The use of a rapid screening test for SARS-CoV-2 viral antigens with high sensitivity could be a useful tool to detect asymptomatic SARS-CoV-2 infected people, and thus be able to carry out events related to leisure in a safe environment.
The aim of this study is to make a mass screening of asymptomatic infection of an (i) experimental group (public attending a massive mass musical show) and (ii) a control group (they will not enter the event) prior to entering to the event.
Randomization 1: 1 by random blocks of the participants with a negative antigen test in the experimental group (attending the event) and the control group (they will not enter the event).
Control with a new Polymerase Chain Reaction (PCR) test 8 days after the event (D8) in the participants of both randomized groups Control of the appearance of symptoms through a questionnaire 10 days after the event (D10), in the participants of both groups with a negative result on day 8.
Validation of a rapid antigen detection test by comparison with the PCR technique.
The indoor activity will include an array of measures designed to reducing the contagion risk, including: mandatory wearing a mask during the event, restricted outdoor areas of bar and smoking, enhanced ventilation of the whole indoor area, and avoiding queues.
All subjects will have downloaded an app in their smart phones to help contact and place tracing during the event, to trace potential transmissions. This app will remain active for 8 days, until the last virologic control.
The inclusion criteria will allow only subjects with an age <60 years, without comorbidities, and who do not live with old adults in their homes, to further reduce the risk of potential complications and transmission to at risk individuals.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The coronavirus disease 2019 (COVID-19) outbreak, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan in December 2019 and has spread globally, representing a serious threat to public health. While 80% of patients are asymptomatic or have a mild illness, 20% develop a severe illness. The predominant symptoms include fever, cough, and myalgia. Mild disease can resolve without medical attention or it can progress to pneumonia and respiratory failure requiring hospitalization. Patients can rapidly progress to acute respiratory distress syndrome (ARDS) with multiple organ dysfunction and death.
The degree to which the virus is infectious during the incubation period is uncertain, but it has been shown that the pharynx reaches peak viral load before day 5, and this peak viral load is 1,000 times higher than in severe acute respiratory syndrome coronavirus (SARS-CoV). This active and high viral clearance from the pharynx at a time when symptoms are still mild makes the transmission of SARS-CoV-2 more efficient than that of SARS-CoV. Later in the disease, COVID-19 resembles SARS in terms of replication in the lower respiratory tract. The decrease in viral load appears to be slow, and there is no sudden shedding of the virus at the time of seroconversion. Seroconversion, at the beginning of week 2, has been observed to coincide with a slow but steady decrease in sputum viral load. Prolonged viral shedding in sputum is relevant not only for infection control in hospitals and discharge management, but also for asymptomatic people who can transmit the virus for longer periods after infection.
Although it is true that the majority of people infected by SARS-CoV-2 will have a benign course with few symptoms, approximately 20% will require hospitalization and 5% will present serious complications and admission to an intensive care unit, this is it translates into a saturation and collapse of health systems, with a high percentage of mortality in relation to it. Unprecedented confinement measures have been implemented that have been effective in containing the progression of the number of infections, but these have had a great social and economic impact, among others with a paralysis of most of the activities related to leisure (concerts , music festivals, theaters, etc.) that are an important component in the economy of most of the countries of the European community. While waiting for highly effective treatments or the development of an effective vaccine, it is necessary to reactivate key economic activities that are related to leisure and culture in an environment that is safest for the participants.
The use of a rapid screening test for SARS-CoV-2 viral antigens with high sensitivity could be a useful tool to detect asymptomatic SARS-CoV-2 infected people, and thus be able to carry out events related to leisure in a safe environment.
It is necessary to implement versatile circuits in which diagnoses with rapid tests can be carried out in the same place of the events in a massive way and to be able to communicate the results of the tests to the assistants at the same time, in order to do this screening of people that they give negative and carry out activities with them in a safe environment for all participants.
The aim of this study is to make a mass screening of asymptomatic infection of an (i) experimental group (public attending a massive mass musical show) and (ii) a control group (they will not enter the event) prior to entering to the event.
Randomization 1: 1 by random blocks of the participants with a negative antigen test in the experimental group (attending the event) and the control group (they will not enter the event).
Control with a new PCR test 8 days after the event (D8) in the participants of both randomized groups Control of the appearance of symptoms through a questionnaire 10 days after the event (D10), in the participants of both groups with a negative result on day 8.
Validation of a rapid antigen detection test by comparison with the PCR technique.
The indoor activity will include an array of measures designed to reducing the contagion risk, including: mandatory wearing a mask during the event, restricted outdoor areas of bar and smoking, enhanced ventilation of the whole indoor area, and avoiding queues.
All subjects will have downloaded an app in their smart phones to help contact and place tracing during the event, to trace potential transmissions. This app will remain active for 8 days, until the last virologic control.
The inclusion criteria will allow only subjects with an age <60 years, without comorbidities, and who do not live with old adults in their homes, to further reduce the risk of potential complications and transmission to at risk individuals.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Barcelona
-
Badalona, Barcelona, Espanha, 08916
- Germans Trias I Pujol Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Adults (age 18-59 years) with interest to attend the scheduled musical event who agree to participate in the study after signing the informed consent, including explicit acceptance of the measures implemented to reduce the risk of transmission of SARS-CoV-2.
- Negative antigen test performed up to 24 h before the event, in nasopharyngeal swab.
Exclusion Criteria:
- Hypertension
- Diabetes Mellitus.
- Ischemic heart disease.
- Any type of Cancer in active treatment.
- Chronic lung diseases such as chronic obstructive pulmonary disease (COPD) and asthma.
- Have a positive test for detection of SARS-CoV-2 by the rapid antigen test
- Who have a body temperature higher than 37.0º on the same day of the event
- Who have a confirmed diagnosis for SARS-CoV-2 in the two weeks prior to the event
- Report any symptoms suggestive of a SARS-CoV-2 infection in the 10 days prior to the study
- Who have been in contact with a person with a confirmed diagnosis of SARS-CoV-2 infection within two weeks prior to the event.
- Living with a person over 70 years of age (inclusive).
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Experimental group
Participate in a massive musical event
|
Participate in a massive musical event
|
Sem intervenção: Control Group
Not participate in a massive musical event
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Incidence rate of people infected with SARS-CoV-2 8 days after randomization
Prazo: At 8 days
|
Incidence rate of people infected with SARS-CoV-2 8 days after randomization, detected by PCR in nasopharyngeal aspirate, on the experimental and the control group.
|
At 8 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
SARS-CoV-2 genome sequence
Prazo: At 8 days
|
Nasopharyngeal swab samples will be stored in case SARS-CoV-2 infections are documented for sequencing purposes to assess the possibility of spreading clusters during the event.
Data will be matched with a Global Positioning System (GPS) smart phone tracking localization during the concert.
|
At 8 days
|
Incidence rate of appearance of symptoms compatible with COVID 19
Prazo: At 10 days
|
Incidence rate of appearance of symptoms compatible with COVID 19 in those attending the event after 10 days (D10).
|
At 10 days
|
Time spent in testing the total number of participants in the study.
Prazo: At day 0
|
Time spent in testing the total number of participants in the study.
|
At day 0
|
Comparison of the diagnostic sensitivity of rapid antigen tests for SARS-CoV-2 compared to PCR in asymptomatic subjects.
Prazo: At day 0
|
We will compare the diagnostic sensitivity of rapid antigen tests for SARS-CoV-2 compared to PCR in asymptomatic subjects.
|
At day 0
|
Comparison of the diagnostic sensitivity of rapid antigen tests for SARS-CoV-2 using a nasopharyngeal swab sample compared to sample obtained trough saliva
Prazo: At day 0
|
We will compare the diagnostic sensitivity of rapid antigen tests for SARS-CoV-2 using a nasopharyngeal swab sample compared to sample obtained trough saliva, in positive cases by this technique.
|
At day 0
|
Presence of viable SARS-CoV-2 from cell culture
Prazo: At day 0
|
Presence of viable SARS-CoV-2 from cell culture in all cases with negative Ag and positive PCR.
|
At day 0
|
Satisfaction in relation to the test procedure
Prazo: At 10 days
|
Assessment of the results obtained on satisfaction in relation to the test procedure of those attending the event through a questionnaire. Questions:
It can be answered with a scale from 0 to 10 (0 not satisfied at all, 10 extremely satisfied) |
At 10 days
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Bonaventura Clotet Sala, PhD, MD, Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- Investigador principal: Boris Revollo Barriga, PhD, MD, Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- Investigador principal: Josep Mª LLIBRRE CODINA, PhD, MD, Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- PRIMACOV
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em COVID-19 (SARS-CoV-2)
-
Mayo ClinicNational Institute of Neurological Disorders and Stroke (NINDS)Recrutamento
-
AstraZenecaAtivo, não recrutando
-
Institute of Tropical Medicine, BelgiumJessa Hospital; University Hospital, Antwerp; Universiteit Antwerpen; Sciensano; M...ConcluídoCOVID-19 | SARS-CoV-2Bélgica
-
SAb Biotherapeutics, Inc.Department of Health and Human Services; JPEO, Chemical, Biological, Radiological...ConcluídoCOVID-19 | SARS-CoV-2Estados Unidos
-
University of Wisconsin, MadisonNational Institutes of Health (NIH)Concluído
-
Syneos HealthUS Specialty Formulations, LLCConcluídoSARS-CoV-2 (COVID-19)Nova Zelândia
-
Mayo ClinicConcluídoCOVID-19 | SARS-CoV-2Estados Unidos
-
University of MelbourneThe George Institute; The University of Queensland; The Peter Doherty Institute... e outros colaboradoresRecrutamentoInfecção por SARS-CoV-2 (COVID-19)Austrália
-
Medical University InnsbruckRecrutamentoSARS-CoV-2 | Síndrome pós-aguda de COVID-19Áustria
-
Dr. Ferrer BioPharmaClinica Union Medica Del Norte, S.A.S., Santiago, República DominicanaAtivo, não recrutandoCOVID-19 | Doença Respiratória Aguda SARS-CoV-2 | Infecção Respiratória COVID-19 | Infecção por SARS CoV 2 | Pandemia do covid-19República Dominicana